Researcher News

Appointment of Professor Carolyn Sue AM to the Kinghorn Chair, Neurodegeneration

Neuroscience Research Australia (NeuRA) and its partners have appointed Professor Carolyn Sue AM as the inaugural Kinghorn Chair, Neurodegeneration. Professor Sue brings with her a team of over 20 clinical and research staff. The appointment is possible through the generous support of the Kinghorn Foundation. They have made a five-year, multi-million dollar philanthropic commitment to Professor Sue’s work to discover and implement new therapeutic solutions to Parkinson’s and mitochondrial disease. Professor Peter Schofield AO, NeuRA’s Chief Executive Officer says, “I am thrilled to welcome Professor Sue into our research community. She brings a wealth of both clinical and research expertise…

Australian researchers awarded €200,000 Wings for Life grant to trial new diagnostic and therapeutic avenues for people with spinal cord injuries

Associate Professor Sylvia Gustin and Dr Monzurul Alam from Neuroscience Research Australia (NeuRA) and UNSW Sydney have been announced as the recipients of a prestigious project grant from the Wings for Life Spinal Cord Injury Foundation. Through this 200,000 Euro grant A/Prof Gustin, Dr Alam and their international collaborators hope to open new diagnostic and therapeutic avenues for people with spinal cord injury. Expanding our understanding of spinal cord injury Every year, around the world, between 250,000 and 500,000 people sustain a spinal cord injury (SCI). In most cases, paralysis is caused by acute damage to the spinal cord following a traumatic injury….

Improving mental wellbeing using positive psychology techniques

There are a lot of tips floating around these days about how to improve or maintain mental wellbeing during lockdowns, but how well do these suggestions work and how long do they take? Many studies assessing wellbeing-boosting activities, known as positive psychology interventions, have been assessed based on face-to-face delivery approaches, using waitlist control groups and typically over the course of two to three months. While positive psychology interventions like acts of kindness, positive reminiscence and self-compassion reflection appear to be effective in these contexts, we wanted to know whether they can be effective when self-administered over shorter timeframes. We…

Is the brain activity elicited by emotion linked to wellbeing?

Stuck at home due to lockdown? How do you feel? Frustrated and angry? Or calm and relaxed knowing that staying at home is the best and quickest way to get out of this situation? The way we process our emotions is crucial in maintaining our mental health and wellbeing. Numerous studies have shown that the better you are at reframing a negative situation into a positive one, the higher your level of wellbeing. However, what has been missing so far is the neural bases of this association – is the brain activity elicited by emotion linked to wellbeing? New research…

NeuRA Awards and Scholarships 2021

NeuRA would like to congratulate the following students and postdoctoral researchers who received scholarships and Awards in 2021.  These scholarships and awards are only possible through the generosity of our donors who sponsor these awards year on year. Thank you, we are truly grateful.   The Grant Broadcasting Fellowship Dr Claire Shepherd The Michael & Elizabeth Gilbert Postgraduate Award in Parkinson’s Disease Research Lloyd Chan The Michael & Elizabeth Gilbert Postgraduate Award in Parkinson’s Disease Research Derya Dik The Janette Mary O’Neil Research Fellowship Dr Jan Fullerton The Cowled Scholarship for Brain Research Abigail Hansen The Betty Fyfe Scholarship Thanwarat…

An Australian perspective on the aducanumab approval by Professor Peter R Schofield

I should start by saying that this is good news. The approval of the first new therapy for Alzheimer’s disease in almost two decades, and the first treatment directed at one of its underlying pathophysiologies, is a critical milestone. The clinical trials showed a reduction in Aβ plaques leading to an expectation of a reduction in clinical decline. I am optimistic because with this advance there will be the opportunity to generate the critical Phase 4 efficacy data required to convert the accelerated approval into a full approval. And I’m also optimistic because clinical proof of the value of this plaque-reducing…